First Midwest Bank Trust Division reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,356 shares of the company’s stock after selling 394 shares during the period. First Midwest Bank Trust Division’s holdings in IDEXX Laboratories were worth $211,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in IDEXX Laboratories by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock valued at $1,495,488,000 after purchasing an additional 354,024 shares in the last quarter. BlackRock Inc. increased its stake in IDEXX Laboratories by 10.5% in the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after purchasing an additional 673,347 shares in the last quarter. Koch Industries Inc. increased its stake in IDEXX Laboratories by 44,533.1% in the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after purchasing an additional 1,396,113 shares in the last quarter. Renaissance Technologies LLC increased its stake in IDEXX Laboratories by 38.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after purchasing an additional 376,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in IDEXX Laboratories by 42.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after purchasing an additional 392,790 shares in the last quarter. 87.63% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://theolympiareport.com/2017/11/02/idexx-laboratories-inc-idxx-shares-sold-by-first-midwest-bank-trust-division.html.

Several equities analysts recently weighed in on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a research note on Wednesday, August 23rd. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price objective for the company in a research note on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $173.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. During the same quarter in the previous year, the company earned $0.62 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 13,000 shares of the company’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the transaction, the chairman now owns 1,044,034 shares of the company’s stock, valued at $157,429,886.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Jonathan W. Ayers sold 58,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $155.00, for a total value of $8,990,000.00. Following the completion of the transaction, the chairman now directly owns 1,043,034 shares in the company, valued at approximately $161,670,270. The disclosure for this sale can be found here. Insiders sold 151,734 shares of company stock worth $23,436,626 in the last ninety days. 2.77% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.